CROSS-REACTIVE MONOCLONAL AND POLYCLONAL ANTIBODIES WHICH RECOGNIZE SURFACE PROTEINS FROM COAGULASE-NEGATIVE STAPHYLOCOCCI AND STAPHYLOCOCCUS AUREUS

• Main Authors: FOSTER, TIMOTHY, J, ROCHE, FIONA, PATTI, JOSEPH, M, PALLEN, MARK, HUTCHINS, JEFF, T, SPEZIALE, PIETRO
• Format: Patent
• Language: English; French
• Published: 25.03.2004
• Edition: 7
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; ENZYMOLOGY; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; TESTING; VINEGAR; WINE

Polyclonal and monoclonal antibodies which are cross-reactive to both coagulase-positive staphylococcus bacteria, such as S. hemolyticus, are provided which can recognize surface proteins from both coagulase-positive and coagulase negative staph bacteria. The antibodies may be generated from surface proteins that have been isolated on the basis of characteristics that may be common between S. aureus and coagulase-negative staphylococci, and these recombinant surface proteins are used to generate the antibodies of the invention. There is also provided vaccines and methods which utilize these proteins and antibodies for the treatment or protection against a wide variety of staphylococcal infections. L'invention concerne des anticorps polyclonaux et monoclonaux qui présentent des réactions croisées aussi bien à l'égard de bactéries de staphylocoques à coagulase positive, p. ex. S. aureus, que de bactéries à coagulase négative, p. ex. S. epidermidis et S. hemolyticus, et sont capables de reconnaître des protéines de surface de bactéries de staphylocoques à coagulase positive et à coagulase négative. Ces anticorps peuvent être produits à partir de protéines de surface qui ont été isolées sur la base de caractéristiques pouvant être communes à S. aureus et à des staphylocoques à coagulase négative, et les protéines de surface recombinées servent à produire les anticorps de l'invention. L'invention concerne aussi des vaccins et des procédés utilisant ces protéines et anticorps pour traiter ou prévenir une large gamme d'infections staphylococciques.